

## Management of Retinopathy of Prematurity (ROP): 80 Years of Vision

**Internet Enduring Material**

**Release Date:** 9/4/2020

**Expiration Date for Credit:** 9/3/2023

*Content was originally presented as part of the MEDNAX Neonatology Grand Rounds series on September 2, 2020.*

**Accreditation:**

The MEDNAX Center for Research, Education, Quality and Safety is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The MEDNAX Center for Research, Education, Quality and Safety designates this Internet Enduring Material for a maximum of 1.00 *AMA PRA Category 1 Credits*<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The MEDNAX Center for Research, Education, Quality and Safety is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. (#PO258)

The MEDNAX Center for Research, Education, Quality and Safety designates this Internet Enduring Material for a maximum of 1.00 *nursing contact hour(s)*. Participants should claim only the credit commensurate with the extent of their participation in the activity.

The MEDNAX Center for Research, Education, Quality and Safety designates this Internet Enduring Material for a maximum of 1.00 *pharmacotherapeutics contact hour(s)*.

**Internet Enduring Material:**

The ACCME recognizes this educational activity as an Internet Enduring Material. The estimated time for completion of this Internet Enduring Material is 60 minutes. This presentation was released on September 4, 2020. The expiration date of this Internet Enduring Material is September 3, 2023.

The ANCC recognizes this educational activity as an Internet Enduring Material. The estimated time for completion of this Internet Enduring Material is 60 minutes. This presentation was released on September 4, 2020. The expiration date of this Internet Enduring Material is September 3, 2023.

**Target Audience:**

This presentation is intended for physicians, advanced practice providers, and other clinicians practicing within the Neonatology specialty.

**Disclosure of Financial Relationships:**

Disclosure of Financial Relationships and Resolution of Conflicts of Interest is designed to ensure quality, objective, balanced, and scientifically rigorous continuing education activities. All individuals in a position to influence and/or control the content of continuing education activities have been asked to disclose all relevant financial relationships within the past 12 months. Any real or apparent conflicts of interest related to the content of the faculty's presentation have been resolved as have any real or apparent conflicts of interest by the planners as related to the content of this conference. Beyond disclosure of relevant financial relationships, faculty are required to disclose when they plan to discuss pharmaceuticals and/or medical devices that are not approved by the FDA and/or medical or surgical procedures that involve an unapproved or "off-label" use of an approved device or pharmaceutical. The MEDNAX Center for Research, Education, Quality and Safety is committed to providing learners with commercially unbiased continuing education activities.

*The planners, moderators or speakers of this activity have the following financial relationship(s) with commercial interests to disclose:*

**C. Armitage Harper III, MD** *Disclosure(s)* – Research and QI projects – Santen, Inc. Lumina; Novartis Pharmaceuticals; Kodiak Sciences, Inc.; Ionis Pharmaceuticals; Genentech, Inc Gallego; Aerie Pharmaceuticals Orion; Graybug Vision. *FDA Disclosures:* Lucentis - off-label; Avastin - off-label; Eyelea - off-label.

**Timothy Biela, MD** *Disclosure(s)* - I have no financial relationships to report.

**Nicole Brenson, MS.Ed** *Disclosure(s)* - I have no financial relationships to report.

**Kassandra S Greci, DNP, APRN, WHNP-BC** *Disclosure(s)* - I have no financial relationships to report.

***Commercial Support:***

There is no commercial support for this educational activity.

***Gap/Purpose:***

Retinopathy of Prematurity is the leading cause of childhood blindness worldwide, but with appropriate treatment techniques, sight limiting outcomes can be largely avoided. Current standards for the treatment of ROP in the US and around the world are not standardized, leading to blindness continuing to occur. This presentation presents a model to safely treat and follow ROP infants, obviating blindness due to retinal pathology.

***Objectives: At the conclusion of this activity, the participant will be able to:***

ACCME Objectives

1. Discuss the current standard of care for the treatment of retinopathy of prematurity.
2. Identify the safe application of anti-vascular endothelial growth factor (anti-VEGF) medication to the infant with retinopathy of prematurity.
3. Illustrate the importance of careful and diligent follow up through the completion of retinal vascularization.

CME – ACGME/ABMS Competencies

1. Patient Care and Procedural Skills
2. Medical Knowledge

ANCC Learning Outcomes

4. Discuss the current standard of care for the treatment of retinopathy of prematurity.
5. Identify the safe application of anti-vascular endothelial growth factor (anti-VEGF) medication to the infant with retinopathy of prematurity.
6. Illustrate the importance of careful and diligent follow up through the completion of retinal vascularization.

ANCC – IOM Competencies

1. Employ evidence-based practice

***Participation and Credit:***

Participants are expected to review all content in the video, access reference materials as needed for additional self-directed learning, take and score 75% or greater correct on the post test, and complete the evaluation in order to earn *AMA PRA Category 1 Credit(s)<sup>™</sup>, nursing contact hour(s), and/or pharmacotherapeutics contact hour(s).*

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of credit for this activity, please consult your professional licensing board.

***Contact:***

Should you have any questions or concerns, please contact us at [Continuing\\_Education@mednax.com](mailto:Continuing_Education@mednax.com)